| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4002988 | American Journal of Ophthalmology | 2013 | 16 Pages |
Abstract
Monthly injections of 2Â mg intravitreal aflibercept for patients with macular edema secondary to CRVO resulted in a statistically significant improvement in visual acuity at week 24, which was largely maintained through week 52 with intravitreal aflibercept PRN dosing. Intravitreal aflibercept injection was generally well tolerated.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
David M. Brown, Jeffrey S. Heier, W. Lloyd Clark, David S. Boyer, Robert Vitti, Alyson J. Berliner, Oliver Zeitz, Rupert Sandbrink, Xiaoping Zhu, Julia A. Haller,